Compare NGL & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | IMCR |
|---|---|---|
| Founded | 1940 | 2008 |
| Country | United States | United Kingdom |
| Employees | 569 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | N/A | 2016 |
| Metric | NGL | IMCR |
|---|---|---|
| Price | $11.57 | $30.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $61.82 |
| AVG Volume (30 Days) | 230.3K | ★ 351.7K |
| Earning Date | 02-03-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | N/A | $14.39 |
| Revenue Next Year | N/A | $8.19 |
| P/E Ratio | $366.01 | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $2.64 | $23.15 |
| 52 Week High | $13.00 | $40.71 |
| Indicator | NGL | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 36.52 |
| Support Level | $11.18 | N/A |
| Resistance Level | $13.00 | $34.86 |
| Average True Range (ATR) | 0.53 | 1.44 |
| MACD | -0.08 | -0.24 |
| Stochastic Oscillator | 31.75 | 6.80 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.